 role HTLV neurologic disease serologic survey antibodies HTLV-I/II course longitudinal study neurologic complications infection Nine seropositive subjects none seronegative control subjects antibodies HTLV-I/II ELISA Western blot polymerase chain reaction presence HTLV-I subjects HTLV-II infection others subjects subject progressive myelopathy identical tropical spastic paraparesis/HTLV-I-associated myelopathy TSP/HAM presence myelopathy resembling TSP/HAM coinfected subjects expression neurologic disease HTLV Patients progressive myelopathy association infection presence HTLV dual infection therapeutic prognostic import subjects corticosteroids subject myelopathy marked improvement absence therapeutic intervention